235 related articles for article (PubMed ID: 28744326)
1. Gut Microbiota-Mediated Personalized Treatment of Hyperlipidemia Using Berberine.
Wang Y; Tong Q; Shou JW; Zhao ZX; Li XY; Zhang XF; Ma SR; He CY; Lin Y; Wen BY; Guo F; Fu J; Jiang JD
Theranostics; 2017; 7(9):2443-2451. PubMed ID: 28744326
[TBL] [Abstract][Full Text] [Related]
2. Effect of Berberine on promoting the excretion of cholesterol in high-fat diet-induced hyperlipidemic hamsters.
Li XY; Zhao ZX; Huang M; Feng R; He CY; Ma C; Luo SH; Fu J; Wen BY; Ren L; Shou JW; Guo F; Chen Y; Gao X; Wang Y; Jiang JD
J Transl Med; 2015 Aug; 13():278. PubMed ID: 26310319
[TBL] [Abstract][Full Text] [Related]
3. The Effects of Berberine on the Gut Microbiota in Apc
Wang H; Guan L; Li J; Lai M; Wen X
Molecules; 2018 Sep; 23(9):. PubMed ID: 30205580
[No Abstract] [Full Text] [Related]
4. A metabolomic and pharmacokinetic study on the mechanism underlying the lipid-lowering effect of orally administered berberine.
Gu S; Cao B; Sun R; Tang Y; Paletta JL; Wu X; Liu L; Zha W; Zhao C; Li Y; Ridlon JM; Hylemon PB; Zhou H; Aa J; Wang G
Mol Biosyst; 2015 Feb; 11(2):463-74. PubMed ID: 25411028
[TBL] [Abstract][Full Text] [Related]
5. Berberine treatment reduces atherosclerosis by mediating gut microbiota in apoE-/- mice.
Shi Y; Hu J; Geng J; Hu T; Wang B; Yan W; Jiang Y; Li J; Liu S
Biomed Pharmacother; 2018 Nov; 107():1556-1563. PubMed ID: 30257374
[TBL] [Abstract][Full Text] [Related]
6. Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (BBR) and facilitates to predict BBR's cholesterol-decreasing efficacy in patients.
Wu C; Zhao Y; Zhang Y; Yang Y; Su W; Yang Y; Sun L; Zhang F; Yu J; Wang Y; Guo P; Zhu B; Wu S
J Adv Res; 2022 Mar; 37():197-208. PubMed ID: 35499044
[TBL] [Abstract][Full Text] [Related]
7. The berberine-enriched gut commensal Blautia producta ameliorates high-fat diet (HFD)-induced hyperlipidemia and stimulates liver LDLR expression.
Yang YN; Wang QC; Xu W; Yu J; Zhang H; Wu C
Biomed Pharmacother; 2022 Nov; 155():113749. PubMed ID: 36174380
[TBL] [Abstract][Full Text] [Related]
8. Transforming berberine into its intestine-absorbable form by the gut microbiota.
Feng R; Shou JW; Zhao ZX; He CY; Ma C; Huang M; Fu J; Tan XS; Li XY; Wen BY; Chen X; Yang XY; Ren G; Lin Y; Chen Y; You XF; Wang Y; Jiang JD
Sci Rep; 2015 Jul; 5():12155. PubMed ID: 26174047
[TBL] [Abstract][Full Text] [Related]
9. Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway.
Sun R; Yang N; Kong B; Cao B; Feng D; Yu X; Ge C; Huang J; Shen J; Wang P; Feng S; Fei F; Guo J; He J; Aa N; Chen Q; Pan Y; Schumacher JD; Yang CS; Guo GL; Aa J; Wang G
Mol Pharmacol; 2017 Feb; 91(2):110-122. PubMed ID: 27932556
[TBL] [Abstract][Full Text] [Related]
10. Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study.
Wang S; Ren H; Zhong H; Zhao X; Li C; Ma J; Gu X; Xue Y; Huang S; Yang J; Chen L; Chen G; Qu S; Liang J; Qin L; Huang Q; Peng Y; Li Q; Wang X; Zou Y; Shi Z; Li X; Li T; Yang H; Lai S; Xu G; Li J; Zhang Y; Gu Y; Wang W
Gut Microbes; 2022; 14(1):2003176. PubMed ID: 34923903
[TBL] [Abstract][Full Text] [Related]
11. Berberine-induced bioactive metabolites of the gut microbiota improve energy metabolism.
Wang Y; Shou JW; Li XY; Zhao ZX; Fu J; He CY; Feng R; Ma C; Wen BY; Guo F; Yang XY; Han YX; Wang LL; Tong Q; You XF; Lin Y; Kong WJ; Si SY; Jiang JD
Metabolism; 2017 May; 70():72-84. PubMed ID: 28403947
[TBL] [Abstract][Full Text] [Related]
12. Integrative analysis of metabolome and gut microbiota in diet-induced hyperlipidemic rats treated with berberine compounds.
Li M; Shu X; Xu H; Zhang C; Yang L; Zhang L; Ji G
J Transl Med; 2016 Aug; 14(1):237. PubMed ID: 27495782
[TBL] [Abstract][Full Text] [Related]
13. Berberine alleviates insulin resistance by reducing peripheral branched-chain amino acids.
Yue SJ; Liu J; Wang AT; Meng XT; Yang ZR; Peng C; Guan HS; Wang CY; Yan D
Am J Physiol Endocrinol Metab; 2019 Jan; 316(1):E73-E85. PubMed ID: 30422704
[TBL] [Abstract][Full Text] [Related]
14. Research progress on berberine with a special focus on its oral bioavailability.
Liu CS; Zheng YR; Zhang YF; Long XY
Fitoterapia; 2016 Mar; 109():274-82. PubMed ID: 26851175
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic interactions between metformin and berberine in rats: Role of oral administration sequences and microbiota.
Lyu Y; Zhang Y; Yang M; Lin L; Yang X; Cheung SCK; Shaw PC; Chan PKS; Kong APS; Zuo Z
Life Sci; 2019 Oct; 235():116818. PubMed ID: 31473193
[TBL] [Abstract][Full Text] [Related]
16. Dose-response effect of berberine on bile acid profile and gut microbiota in mice.
Guo Y; Zhang Y; Huang W; Selwyn FP; Klaassen CD
BMC Complement Altern Med; 2016 Oct; 16(1):394. PubMed ID: 27756364
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects.
Li G; Zhao M; Qiu F; Sun Y; Zhao L
Drug Des Devel Ther; 2019; 13():129-139. PubMed ID: 30587933
[TBL] [Abstract][Full Text] [Related]
18. Effects of type 2 diabetes mellitus on the pharmacokinetics of berberine in rats.
Jia Y; Xu B; Xu J
Pharm Biol; 2017 Dec; 55(1):510-515. PubMed ID: 27937081
[TBL] [Abstract][Full Text] [Related]
19. [Efficient and rapid liquid reduction animal model].
Han B; Kou SM; Chen B; Peng YZ; Wang Y; Han YL; Ye XL; Li XG
Zhongguo Zhong Yao Za Zhi; 2015 Nov; 40(22):4446-51. PubMed ID: 27097422
[TBL] [Abstract][Full Text] [Related]
20. Berberine treatment-emergent mild diarrhea associated with gut microbiota dysbiosis.
Yue SJ; Liu J; Wang WX; Wang AT; Yang XY; Guan HS; Wang CY; Yan D
Biomed Pharmacother; 2019 Aug; 116():109002. PubMed ID: 31154270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
